DOCSLIB.ORG

A Role for the Hydroxybenzoic Acid Metabolites of Flavonoids And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Role for the Hydroxybenzoic Acid Metabolites of Flavonoids And A ROLE FOR THE HYDROXYBENZOIC ACID METABOLITES OF FLAVONOIDS AND ASPIRIN IN THE PREVENTION OF COLORECTAL CANCER BY RANJINI SANKARANARAYANAN A dissertation submitted in partial fulfillment of the requirements for the Doctor of Philosophy Major in Pharmaceutical Sciences South Dakota State University 2021 ii DISSERTATION ACCEPTANCE PAGE Ranjini Sankaranarayanan This dissertation is approved as a creditable and independent investigation by a candidate for the Doctor of Philosophy degree and is acceptable for meeting the dissertation requirements for this degree. Acceptance of this does not imply that the conclusions reached by the candidate are necessarily the conclusions of the major department. Gunaje Jayarama, A00137123 Advisor Date Omathanu Perumal Department Head Date Nicole Lounsbery, PhD Director, Graduate School Date iii ACKNOWLEDGEMENTS The completion of this work would not have been possible without the help and contribution of various people who have in their own kind way supported its accomplishment. I would like to express my heart-felt gratitude to my mentor Dr. Jayarama Bhat Gunaje for having skillfully guided me through this project and for having generously extended his support throughout. Dr. Jay has taught me invaluable lessons about honesty, integrity, and listening to your data when it comes to scientific research. He has always been a pillar of support and has also been kind in sharing his many experiences to help me both professionally and personally. I thank him for this. These four years that I spent in the lab with him will be time I will fondly remember and cherish forever. I would like to thank Dr. Joy Scaria (Department of Veterinary & Biomedical Sciences, SDSU) and Dr. Hemachand Tummala for their valuable advice and for graciously allowing me to use their laboratory facilities and resources for the completion of this work. I would like to thank my committee members Dr. Xingyou Gu and Dr. Suvobrata Chakravarty for their critical inputs and valuable suggestions during the course of this investigation. I am also extremely thankful to Dr. Theresa Seefeldt, Dr. D. Ramesh Kumar (University of Kentucky), and Dr. Severine Van slambrouck (Department of Chemistry and Biochemistry, SDSU) for all their encouragement, timely advice and help for the progression of my project. Each of them in their own kind way have been instrumental to for the completion of this work. This is especially true of Dr. Ramesh Kumar, who helped me out immensely with the bioinformatics section of the project and patiently guided me iv to better understand this field. I would also like to take this opportunity to thank Dr. Puttur Prasad (Medical College of Georgia at Augusta University) for providing us with the transporter-expressing cancer cell line. A large part of my thesis would have been incomplete without the use of this critical cell line. I am extremely grateful to him for his generosity. I am also grateful to Fraunhofer, Center for Molecular Biotechnology, USA, for providing me with an internship opportunity. My experience there helped me understand the nuances of drug delivery and allowed me to apply the theoretical knowledge I gained in my Ph.D. coursework into practice. It was an enriching experience and I thank them for this. I would love to thank my colleagues, seniors and friends for providing an amazing environment to work in, these last 4 years. I would especially like to thank Dr. Rakesh Dachineni, Maria and Linto Antony and their family, Shruti S. Menon, Prabhjot Kaur Sekhon, Ekavali Sharma, Mawuli MacDonald, Chaitanya Valiveti, Dr. Mibin Joseph, Dr. Somshuvra Bhattacharya, Emily Trias and Tana Lick, for their unwavering support and belief in me. My stay in Brookings was made pleasant because of these wonderful individuals who helped me make a home away from home. I would sincerely like to thank Dr. Omathanu Perumal (the Head), Dr. Xiangming Guan (Graduate Research Coordinator), and all the faculty and staff of the Pharmaceutical Sciences Department for their constant support and encouragement during the course of my stay at SDSU. I would also like to thank them for offering me the opportunity to be the laboratory manager for the last three years. It taught me important lessons in people management and leadership. v I would also like to take this opportunity to thank the department of Pharmaceutical Sciences for their financial support and for providing me with all the facilities and resources required for the successful completion of this project. Last but not the least, I would like to thank my family – my grandmother, parents, sister and brother-in-law without whose support and encouragement this journey would not have been complete. I extend my heartfelt gratitude to them all. _________________________________ Ranjini Sankaranarayanan vi CONTENTS ABBREVIATIONS ......................................................................................................... xiii LIST OF FIGURES ........................................................................................................ xvii LIST OF TABLES ............................................................................................................ xx ABSTRACT ..................................................................................................................... xxi CHAPTER 1: INTRODUCTION ....................................................................................... 1 1.1 Colorectal cancer (CRC) ........................................................................................... 3 1.1.1 Tumor suppressor genes and protooncogenes as drivers of CRC development . 4 1.1.1.1 APC and development of CRC .............................................................. 5 1.1.1.2 Tumor protein P53 (P53) and development of CRC: .................................. 5 1.1.1.3 SMAD4 and development of CRC .............................................................. 6 1.1.1.4 RAS and BRAF and development of CRC ................................................... 7 1.1.1.5 PI3K signaling and development of CRC .................................................... 7 1.2 Cell cycle regulation and cancer development .......................................................... 8 1.2.1 Dysregulation of the cell cycle in cancer: ........................................................ 11 1.2.2 CDKs ................................................................................................................ 12 1.2.3 Cyclins .............................................................................................................. 12 1.2.4 CDK activating enzymes .................................................................................. 13 1.2.5 CKIs .................................................................................................................. 13 1.2.6 CDK Substrates ................................................................................................ 14 vii 1.2.7 Checkpoint proteins .......................................................................................... 14 1.3 CDK inhibitors for cancer treatment ....................................................................... 14 1.3.1 Targeted inhibition of CDK4 and CDK6 ......................................................... 15 1.4 Cancer chemoprevention ......................................................................................... 17 1.4.1 Drugs as agents of cancer prevention ............................................................... 17 1.4.2 Phytochemicals as agents of cancer prevention ............................................... 19 1.5 Flavonoids in cancer prevention ............................................................................. 20 1.5.1 Flavonoid effects on signal transduction .......................................................... 21 1.5.2 Antioxidant effects of flavonoids ..................................................................... 23 1.6 Aspirin as a chemopreventive agent........................................................................ 23 1.6.1 Pharmacological effects of Aspirin .................................................................. 24 1.6.2 Mechanisms proposed for aspirin’s chemo-preventive effects. ....................... 25 1.6.2.1 Inhibition of COX enzymes: the platelet hypothesis ................................. 25 1.6.2.2 Inhibition of Nuclear Factor (NF)-κB signaling ........................................ 29 1.6.2.3 Activation of AMP-kinase and inhibition of mTOR signaling .................. 29 1.6.2.4 Inhibition of Wnt signaling and β-catenin phosphorylation ...................... 30 1.6.2.5 Downregulation of c-myc, cyclin A2 and CDK2 ...................................... 30 1.6.2.6 Induction of polyamine catabolism ............................................................ 31 1.6.2.7 Induction of DNA mismatch repair proteins ............................................. 31 viii 1.6.2.8 Acetylation of P53, glucose-6-phosphate dehydrogenase and other proteins ................................................................................................................................ 32 1.6.2.9 Other mechanisms ...................................................................................... 33 1.7 Metabolism of flavonoids ....................................................................................... 34 1.8 Metabolism of aspirin.............................................................................................. 37 1.9 Biotransformation
Load more

Recommended publications
  • Genes Involved in Virulence of the Entomopathogenic Fungus Beauveria Bassiana Chapter 3
    A multidisciplinary approach to study virulence of the entomopathogenic fungus Beauveria bassiana towards malaria mosquitoes Claudio A. Valero Jiménez Thesis committee Promotors Prof. Dr B.J. Zwaan Professor of Genetics Wageningen University Prof. Dr W. Takken Personal chair at the Laboratory of Entomology Wageningen University Co-promotors Dr. C.J.M. Koenraadt Assistant professor, Laboratory of Entomology Wageningen University Dr. J.A.L. van Kan Assistant professor, Laboratory of Phytopathology Wageningen University Other members Prof. Dr M.E. Schranz, Wageningen University Dr V.I.D. Ros, Wageningen University Dr M. Rep, University of Amsterdam Prof. Dr J. Eilenberg, University of Copenhagen, Denmark This research was conducted under the auspices of the C.T. de Wit Graduate School for Production Ecology and Resource Conservation A multidisciplinary approach to study virulence of the entomopathogenic fungus Beauveria bassiana towards malaria mosquitoes Claudio A. Valero Jiménez Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr A.P.J. Mol, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Wednesday 21 September 2016 at 4 p.m. in the Aula. Claudio A. Valero Jiménez A multidisciplinary approach to study virulence of the entomopathogenic fungus Beauveria bassiana towards malaria mosquitoes. 131 pages. PhD thesis, Wageningen University, Wageningen, NL (2016) With references, with summary in
    [Show full text]
  • Flavonoid-Modifying Capabilities of the Human Gut Microbiome—An in Silico Study
    nutrients Article Flavonoid-Modifying Capabilities of the Human Gut Microbiome—An In Silico Study Tobias Goris 1,* , Rafael R. C. Cuadrat 2 and Annett Braune 1 1 Research Group Intestinal Microbiology, Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany; [email protected] 2 Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany; [email protected] * Correspondence: [email protected] Abstract: Flavonoids are a major group of dietary plant polyphenols and have a positive health impact, but their modification and degradation in the human gut is still widely unknown. Due to the rise of metagenome data of the human gut microbiome and the assembly of hundreds of thousands of bacterial metagenome-assembled genomes (MAGs), large-scale screening for potential flavonoid-modifying enzymes of human gut bacteria is now feasible. With sequences of characterized flavonoid-transforming enzymes as queries, the Unified Human Gastrointestinal Protein catalog was analyzed and genes encoding putative flavonoid-modifying enzymes were quantified. The results revealed that flavonoid-modifying enzymes are often encoded in gut bacteria hitherto not considered to modify flavonoids. The enzymes for the physiologically important daidzein-to-equol conversion, well studied in Slackia isoflavoniconvertens, were encoded only to a minor extent in Slackia MAGs, but were more abundant in Adlercreutzia equolifaciens and an uncharacterized Eggerthellaceae species. In addition, enzymes with a sequence identity of about 35% were encoded in highly abundant MAGs of uncultivated Collinsella species, which suggests a hitherto uncharacterized daidzein-to-equol potential in these bacteria.
    [Show full text]
  • Gut-Derived Flavonifractor Species Variants Are Differentially Enriched
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.30.890848; this version posted December 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Gut-derived Flavonifractor species variants are 2 differentially enriched during in vitro incubation with 3 quercetin 4 Short Title: Flavonifractor species variants are differentially enriched during incubation with 5 quercetin 6 Gina Paola Rodriguez-Castaño 1*, Federico E. Rey2, Alejandro Caro-Quintero3, Alejandro 7 Acosta-González1 8 1 Engineering Department, La Sabana University, Chia, Colombia 9 2 Department of Bacteriology, University of Wisconsin-Madison, USA 10 3 AGROSAVIA, Centro de Investigación Tibaitatá, Mosquera, Colombia. 11 * Correspondence: 12 Gina Paola Rodriguez-Castaño 13 [email protected] (GRC) 14 15 Abstract 16 Flavonoids are a common component of the human diet with widely reported health- 17 promoting properties. The gut microbiota transforms these compounds affecting the overall 18 metabolic outcome of their consumption. Flavonoid-degrading bacteria are often studied in 19 isolation under culture conditions that do not resemble the conditions in the colon and that bioRxiv preprint doi: https://doi.org/10.1101/2019.12.30.890848; this version posted December 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • GRAS Notice (GRN) No.901, Glucosyl Hesperidin
    GRAS Notice (GRN) No. 901 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory ~~~lECTV!~ITJ) DEC 1 2 20,9 OFFICE OF FOOD ADDITI\/c SAFETY tnC Vanguard Regulator~ Services, Inc 1311 Iris Circle Broomfield, CO, 80020, USA Office: + 1-303--464-8636 Mobile: +1-720-989-4590 Email: [email protected] December 15, 2019 Dennis M. Keefe, PhD, Director, Office of Food Additive Safety HFS-200 Food and Drug Administration 5100 Paint Branch Pkwy College Park, MD 20740-3835 Re: GRAS Notice for Glucosyl Hesperidin Dear Dr. Keefe: The attached GRAS Notification is submitted on behalf of the Notifier, Hayashibara Co., ltd. of Okayama, Japan, for Glucosyl Hesperidin (GH). GH is a hesperidin molecule modified by enzymatic addition of a glucose molecule. It is intended for use as a general food ingredient, in food. The document provides a review of the information related to the intended uses, manufacturing and safety of GH. Hayashibara Co., ltd. (Hayashibara) has concluded that GH is generally recognized as safe (GRAS) based on scientific procedures under 21 CFR 170.30(b) and conforms to the proposed rule published in the Federal Register at Vol. 62, No. 74 on April 17, 1997. The publically available data and information upon which a conclusion of GRAS was made has been evaluated by a panel of experts who are qualified by scientific training and experience to assess the safety of GH under the conditions of its intended use in food. A copy of the Expert Panel's letter is attached to this GRAS Notice.
    [Show full text]
  • Characteristics of Flavonoids in Niihime Fruit - a New Sour Citrus Fruit
    Food Sci. Technol. Res., +, (-), +20ῌ+3-, ,**0 Characteristics of Flavonoids in Niihime Fruit - a New Sour Citrus Fruit ῌ Yoshiaki MIYAKE Faculty of Human Wellness, Tokaigakuen University, Nagoya, .02ῌ2/+., Japan Received November ,+, ,**/; Accepted June ,, ,**0 Niihime fruit, produced in the coastal area of the Sea of Kumano in Mie prefecture, is a new sour citrus fruit. This is the first study to examine the characteristics of the flavonoids in niihime fruit. The content of flavonoids in the juice and peel of niihime fruit was determined by HPLC and their distribution was examined in comparison with seven other species of sour citrus fruits. Niihime fruit was found to contain a comparatively high quantity of bioactive flavonoids of the flavanone glycosides with rutinose sugar chain such as eriocitrin and hesperidin as well as the polymethoxyflavones such as nobiletin and tangeretin. The peel extract of niihime fruit exhibited comparatively high antioxidative activity among sour citrus fruits using the DPPH radical scavenging assay. Furthermore, the flavonoids eluted from niihime fruit by over time in hot and cold solutions of water, /ῌ ethanol, and ,/ῌ ethanol, which are commonly used in the field of food processing and cooking, were examined. The flavonoids eluted from niihime fruit in hot ,/ῌ ethanol solution was highest content in solutions, and the content of flavonoids eluted in / min was an approximate half of content eluted in 0* min. The flavanone glycosides, eriocitrin and hesperidin, were eluted in higher contents in hot solutions than in cold solutions. The polymethoxyflavones, nobiletin and tangeretin, were eluted to some extent in hot /ῌ ethanol but were found in low contents in cold solutions.
    [Show full text]
  • Bioavailability and Metabolic Pathway of Phenolic Compounds Muhammad Bilal Hussain, Sadia Hassan, Marwa Waheed, Ahsan Javed, Muhammad Adil Farooq and Ali Tahir
    Chapter Bioavailability and Metabolic Pathway of Phenolic Compounds Muhammad Bilal Hussain, Sadia Hassan, Marwa Waheed, Ahsan Javed, Muhammad Adil Farooq and Ali Tahir Abstract As potential agents for preventing different oxidative stress-related diseases, phenolic compounds have attracted increasing attention with the passage of time. Intake of fruits, vegetables and cereals in higher quantities is linked with decreased chances of chronic diseases. In plant-based foods, phenolic com- pounds are very abundant. However, bio-accessibility and biotransformation of phenolic compound are not reviewed in these studies; therefore, a detailed action mechanism of phenolic compounds is not recognized. In this article, inclusive concept of different factors affecting the bioavailability of phenolic compounds and their metabolic processes is presented through which phenolic compounds go after ingestion. Keywords: polyphenols, bioavailability, biotransformation, metabolism 1. Introduction In recent past, the awareness of the consumer related to the effect of diet on the health has been improved; therefore, leading to upsurge in the con- sumption of vegetables, cereal based foods and fruits. Numerous studies have suggested the bioactive characteristics of the bioactive moieties, i.e., phenolic compounds. Nonetheless, bioactive claims are made without taking into consid- eration the further modifications to which phenolic compounds are subjected once ingested [1]. Phenolic compounds are the secondary metabolites of plants which consti- tute an important group, i.e., phenylpropanoids. These compounds possess an aromatic ring and various OH groups which are link to it. On the basis of clas- sification, phenolic compounds are prorated into various subgroups. They are grouped as a function of the number of phenolic rings that they contain and the radicals that bind these rings to another one [2, 3].
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur Et Al
    USOO89628OOB2 (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur et al. (45) Date of Patent: Feb. 24, 2015 (54) NUCLEICACIDS AND PROTEINS AND USPC .......................................................... 530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Naperville, IL (US) PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Nolling etal (J. Bacteriol. 183: 4823 (2001).* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 0 days. Isolates of Pseudomonas aeruginosa J. Bacteriol. (2003) 185: 1316-1325. (21) Appl. No.: 13/400,365 2002.Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (22) Filed: Feb. 20, 2012 bor New York, 2001, pp. 382-393. O O Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (65) Prior Publication Data toxicology” Toxicol. Lett. (2000) 1.12: 365-370. US 2012/O266329 A1 Oct. 18, 2012 * cited by examiner Related U.S. Application Data - - - Primary Examiner — James Martinell (62) Division of application No. 1 1/817,403, filed as (74) Attorney, Agent, or Firm — DLA Piper LLP (US) application No. PCT/US2006/007642 on Mar. 3, 2006, now Pat. No. 8,119,385. (57) ABSTRACT (60) Provisional application No. 60/658,984, filed on Mar. The invention provides polypeptides, including enzymes, 4, 2005.
    [Show full text]
  • Note Preparation of a Lemon Flavonoid Aglycone and Its
    Food Sci. Technol. Res., 15 (1), 83–88, 2009 Note Preparation of a Lemon Flavonoid Aglycone and its Suppressive Effect on the Susceptibility of LDL to Oxidation Following Human Ingestion 1* 2 2 3 2 Yoshiaki MIYAKE , Chika SAKURAI , Mika USUDA , Masanori HIRAMITSU and Kazuo KONDO 1 Faculty of Human Wellness, Tokaigakuen University, Nagoya 468-8514, Japan 2 Institute of Environmental Science for Human Life, Ochanomizu University, Tokyo 112-8610, Japan 3 Pokka Corporation Ltd., Kitanagoya City, Aichi 481-8515, Japan Received July 4, 2008; Accepted September 5, 2008 Lemon flavonoid (LF) prepared from lemon peel predominantly contains eriocitrin as an antioxidant. It is indicated to have low bioavailability compared with lemon flavonoid aglycone (LFA), which predomi- nantly contains eriodictyol. This study attempted to prepare LFA which has high bioavailability, using enzymes that are commonly used in the citrus industry, such as cellulase, naringinase, hesperidinase, and pectinase. LFA containing the highest amount of eriodictyol (19.4%) was prepared with naringinase, a debittering enzyme for citrus juice. Ten male normolipidemic subjects ingested LFA (3.7 g) after an over- night fast, and low-density lipoprotein (LDL) was prepared from 0-4 h plasma after intake of LFA. The LDL oxidizability was measured with lag time of the conjugated diene formation induced by an oxidative inducer. LDL in 0.5 h plasma after ingestion of LFA was shown to have a significantly longer lag time for oxidation than that before ingestion (P<0.05). LFA was suggested to have the resistance effect of LDL to oxidation ex vivo. Eriodictyol, homoeriodictyol, and hesperetin were not detected in plasma by HPLC analysis, but they were detected in plasma treated with β-glucuronidase and sulfatase.
    [Show full text]
  • Hydrolysis of the Rutinose-Conjugates Flavonoids Rutin and Hesperidin by the Gut Microbiota and Bifidobacteria
    Nutrients 2015, 7, 2788-2800; doi:10.3390/nu7042788 OPEN ACCESS nutrients ISSN 2072-6643 www.mdpi.com/journal/nutrients Article Hydrolysis of the Rutinose-Conjugates Flavonoids Rutin and Hesperidin by the Gut Microbiota and Bifidobacteria Alberto Amaretti, Stefano Raimondi, Alan Leonardi, Andrea Quartieri and Maddalena Rossi * Department of Life Sciences, University of Modena and Reggio Emilia, via Campi 183, 41125 Modena, Italy; E-Mails: [email protected] (A.A.); [email protected] (S.R.); [email protected] (A.L.); [email protected] (A.Q.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-059-2055567. Received: 26 February 2015 / Accepted: 7 April 2015 / Published: 14 April 2015 Abstract: Flavonols and flavanones are polyphenols exerting many healthy biological activities. They are often glycosylated by rutinose, which hampers absorption in the small intestine. Therefore they require the gut microbiota to release the aglycone and enable colonic absorption. The role of the gut microbiota and bifidobacteria in the release of the aglycones from two major rutinosides, hesperidin and rutin, was investigated. In bioconversion experiments, the microbiota removed rutinose from both rutin and hesperidin, even though complete hydrolysis was not obtained. To investigate whether bifidobacteria can participate to the hydrolysis of rutinosides, 33 strains were screened. Rutin was resistant to hydrolysis by all the strains. Among six tested species, mostly Bifidobacterium catenulatum and Bifidobacterium pseudocatenultum were able to hydrolyze hesperidin, by means of a cell-associated activity. This result is in agreement with the presence of a putative α-L-rhamnosidase in the genome of B.
    [Show full text]
  • AVANCES EN ALIMENTACION FUNCIONAL.Pdf
    2 AVANCES EN LA INVESTIGACIÓN DE LA ALIMENTACIÓN FUNCIONAL ANEXO:IJornada CYTEDIBEROFUNSOBRE ALIMENTACIÓNSALUD MEXICO2010 Editor:F.JavierFontechaAlonso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ÍNDICE GENERAL Agradecimientos Introducción …..………………………………………………………….…………….……………….….9 Capítulo 1.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Structural and Biochemical Characterization of the Dual Substrate Recognition of the (R)-Selective Amine Transaminase from Aspergillus Fumigatus
    Struktur und Funktion der ersten bakteriellen Chalconisomerase und einer (R)-selektiven Amin-Transaminase I n a u g u r a l d i s s e r t a t i o n zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Ernst-Moritz-Arndt-Universität Greifswald vorgelegt von Maren Thomsen geboren am 23.01.1988 in Itzehoe Greifswald, Dezember 2014 Dekan: Prof. Dr. Klaus Fesser 1. Gutachter: Prof. Dr. Winfried Hinrichs 2. Gutachter: Prof. Dr. Norbert Sträter Tag der Promotion: 25. Februar 2015 Inhaltsverzeichnis Inhaltsverzeichnis Seite 1. Einleitung 1 2. Einleitung zu Chalconisomerasen 2 2.1 Flavonoide 2 2.2 Pflanzliche Chalconisomerasen 3 2.3 Reaktionsmechanismus der pflanzlichen Chalconisomerasen 5 2.4 Degradation der Flavonoide durch die intestinale Mikroflora 6 3. Ergebnisse zur Chalconisomerase aus Eubacterium ramulus 8 3.1 De novo Strukturlösung der bakteriellen CHI mittels SIRAS 8 3.2 Strukturanalyse der bakteriellen CHI aus E. ramulus 8 3.3 Aktives Zentrum und Reaktionsmechanismus 9 3.4 Bedeutung des Lids für die bakterielle CHI 10 3.5 Suche nach Faltungshomologen zur bakteriellen CHI 11 4. Einleitung zu (R)-selektiven Amin-Transaminasen 13 5. Ergebnisse zur (R)-selektiven Amin-Transaminase aus Aspergillus fumigatus 18 5.1 Kristallisation und Röntgendiffraktion der (R)-selektiven Amin-Transaminase 18 5.2 Strukturanalyse der (R)-selektiven Amin-Transaminase 18 5.3 Untersuchungen zur dualen Substraterkennung der (R)-selektiven Amin- Transaminase 20 6. Literatur 22 7. Publikationsliste 28 Einleitung 1. Einleitung Proteine können eine Vielzahl an unterschiedlichen Funktionen ausüben. Darunter fallen Aufgaben wie die Übernahme von Stützfunktionen zum Aufbau des Zytoskeletts, andere übernehmen Transportprozesse und vermitteln den gerichteten Stofftransport in der Zelle.
    [Show full text]